Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY58.18 CNY
Change Today +0.39 / 0.67%
Volume 2.3M
As of 3:00 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

livzon pharmaceutical grou-a (000513) Snapshot

Open
CNY58.15
Previous Close
CNY57.79
Day High
CNY58.32
Day Low
CNY56.50
52 Week High
03/26/15 - CNY59.10
52 Week Low
04/30/14 - CNY40.20
Market Cap
14.9B
Average Volume 10 Days
2.9M
EPS TTM
CNY1.74
Shares Outstanding
183.7M
EX-Date
--
P/E TM
33.4x
Dividend
CNY0.10
Dividend Yield
0.86%
Current Stock Chart for LIVZON PHARMACEUTICAL GROU-A (000513)

Related News

No related news articles were found.

livzon pharmaceutical grou-a (000513) Related Businessweek News

No Related Businessweek News Found

livzon pharmaceutical grou-a (000513) Details

Livzon Pharmaceutical Group Inc. is engaged in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China and internationally. Its products primarily include Chinese and Western drug preparation products, such as Shengqi Fuzheng Injection, a series of Bismuth Potassium Citrate Granules products, anti-viral granules, Urofollitropin for injection, Menotropins for injection, Ilaprazole, Leuprorelin Acetate Microspheres for injection, Cefodizime Sodium for injection, Voriconazole for injection, and mouse nerve growth factor for injection. The company’s products also comprise bulk medicines and intermediates, including Mevastatin, Colistin, Phenylalanine, Ceftriaxone Sodium, Cefuroxime Sodium, and Cefodizime Sodium; and diagnostic reagent products, such as ELISA HIV testing reagent, MYCOII testing reagent, and TPPA testing reagent. In addition, the company provides chemical drugs, biochemical drugs, microbiological preparations, and antibiotics; polypeptide bulk medicines; diagnostic reagents and equipment; human chorionic Gonadotrophin for injection; Omeprazole Sodium for injection; Ranitidine Bismuth Citrate tablets; Valaciclovir Hydrochloride tablets; Fluvoxamine Maleate tablet; Perospirone Hydrochloride tablets; and Prostant used for the treatment of clearing away heat evil and promoting diuresis. Further, it manufactures fermented antibiotics, sterile cephalosporins, and hypolipidemic statin. Livzon Pharmaceutical Group Inc. was founded in 1985 and is based in Zhuhai, China.

5,544 Employees
Last Reported Date: 03/23/15
Founded in 1985

livzon pharmaceutical grou-a (000513) Top Compensated Officers

Vice Chairman, President, Member of Nominatio...
Total Annual Compensation: CNY686.4K
Chief Supervisor
Total Annual Compensation: CNY248.6K
Chief Supervisor
Total Annual Compensation: --
Supervisor
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

livzon pharmaceutical grou-a (000513) Key Developments

Livzon Pharmaceutical Group Inc Announces the Profit Distribution Proposal for 2014

Livzon Pharmaceutical Group Inc. announced the profit distribution proposal for 2014 as Cash dividend of CNY 1.00000000 (tax included) per 10 shares.

Livzon Pharmaceutical Group Inc. Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2014

Livzon Pharmaceutical Group Inc. reported audited consolidated earnings results for the year ended December 31, 2014. For the year, the company reported total operating income of RMB 5,544,233,777.86 compared to RMB 4,618,680,040.86 a year ago. Operating profit was RMB 584,508,541.09 compared to RMB 590,556,920.08 a year ago. Profit before income tax was RMB 652,025,033.87 compared to RMB 628,940,453.70 a year ago. Net profit attributable to the shareholders of the parent company was of RMB 515,978,431.82 or RMB 1.74 per diluted share compared to RMB 487,502,351.80 or RMB 1.65 per diluted share a year ago. Net cash flows from operating activities were RMB 717,393,893.55 compared to RMB 439,986,525.69 a year ago. Cash paid for acquisition of fixed assets, intangible assets and other long-term assets were RMB 665,519,169.35 compared to RMB 920,001,234.77 a year ago.

Livzon Pharmaceutical Group Inc., Board Meeting, Mar 23, 2015

Livzon Pharmaceutical Group Inc., Board Meeting, Mar 23, 2015. Agenda: To consider annual results of the company and its subsidiaries for the year ended 31 December 2014; to consider the recommendation of final dividend, if any; and to transact any other business.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
000513:CH CNY58.18 CNY +0.39

000513 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 000513.
View Industry Companies
 

Industry Analysis

000513

Industry Average

Valuation 000513 Industry Range
Price/Earnings 33.4x
Price/Sales 3.1x
Price/Book 4.6x
Price/Cash Flow 20.7x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIVZON PHARMACEUTICAL GROU-A, please visit www.livzon.com.cn/english/. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.